Successful infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in two Taiwanese children: An experience from a medical center

Pediatr Neonatol. 2024 May;65(3):305-307. doi: 10.1016/j.pedneo.2023.12.002. Epub 2023 Dec 27.

Authors

Chun-Ting Liu¹, G W Gant Luxton², Chia-Cheng Sung¹, Fu-Min Wang¹, Chia-Ning Chang¹, Chih-Fen Hu³

Affiliations

¹ Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.
² Department of Molecular and Cellular Biology, University of California-Davis, Davis, CA, USA.
³ Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. Electronic address: caperhu@gmail.com.

PMID: 38169192
DOI: 10.1016/j.pedneo.2023.12.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

COVID-19 Drug Treatment
COVID-19* / complications
Child
Humans
Infliximab* / therapeutic use
SARS-CoV-2
Systemic Inflammatory Response Syndrome* / drug therapy
Systemic Inflammatory Response Syndrome* / etiology
Taiwan

Substances

Infliximab

Supplementary concepts

pediatric multisystem inflammatory disease, COVID-19 related